beta-amyloid

On cognitive reframing and biases, stress, mental health tech, Aduhelm backlash, Britney Spears, and more

by

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing this time nine sci­en­tif­ic reports and indus­try devel­op­ments to help pro­mote life­long brain and men­tal health.

#1. To low­er stress lev­els and improve prob­lem-solv­ing, prac­tice cog­ni­tive refram­ing instead of venting

“… vent­ing like­ly doesn’t soothe anger as much as aug­ment it. That’s because encour­ag­ing peo­ple to act out their anger makes them relive it in their bod­ies, strength­en­ing the neur­al path­ways for anger and mak­ing it eas­i­er to get angry the next time around. Stud­ies on vent­ing anger (with­out effec­tive feed­back), whether online or ver­bal­ly, have also found it to be gen­er­al­ly unhelp­ful … To get out of that, you can ask the per­son to step back and help you reframe your expe­ri­ence by ask­ing, “How should I think about this dif­fer­ent­ly?” or “What should I do in this situation?”

#2. Head­space and Gin­ger merge to expand and scale up dig­i­tal men­tal health

“The new com­pa­ny would find it push­ing well beyond its cur­rent mind­ful­ness focus to, “pro­vide the full spec­trum of proven, effec­tive vir­tu­al sup­port – from mind­ful­ness and med­i­ta­tion, to text-based behav­ioral health coach­ing, to video-based ther­a­py and psy­chi­a­try – for all types of patient populations.”

Ambi­tious move!

#3. How to read, under­stand and write great med­ical research

12 good tips for stu­dents and every­one else

#4. Vet­er­ans Affairs won’t cov­er Biogen’s new “Alzheimer’s drug” giv­en con­cerns over safe­ty and lack of evidence

Their inde­pen­dent review con­cludes that “giv­en the lack of evi­dence of a robust and mean­ing­ful clin­i­cal ben­e­fit and the known safe­ty sig­nal, we rec­om­mend against offer­ing this agent to patients with Alzheimer’s demen­tia (mild or oth­er­wise) or mild cog­ni­tive impairment.”

#5. Alzheimer’s & Demen­tia researchers chal­lenge FDA’s approval of Aduhelm giv­en lack of evi­dence for beta-amy­loid as a marker

A strong call to “learn how this reg­u­la­to­ry fail­ure occurred and to ensure that it doesn’t occur again”

#6. Debunk­ing four myths about deci­sion-mak­ing capac­i­ty to keep Brit­ney Spears and oth­ers safe

Address­ing the ongo­ing con­tro­ver­sy about con­ser­va­tor­ships, a USC Pro­fes­sor of Law, Psy­chol­o­gy, and Psy­chi­a­try shares a great arti­cle to debunk these all-too-com­mon myths

#7. Study exam­ines com­mon cog­ni­tive bias­es (have you tried this brain teas­er?) and ways to mit­i­gate them

If you have not encoun­tered the “Lin­da brain teas­er” before, please give it a try! If you have, you’ll enjoy the new paper titled Tver­sky and Kahneman’s Cog­ni­tive Illu­sions: Who Can Solve Them, and Why?

#8. Inte­grat­ing music, move­ment and stroke reha­bil­i­ta­tion, MedRhythms rais­es $25M to devel­op and com­mer­cial­ize dig­i­tal therapeutic

Fas­ci­nat­ing approach to gait training.

#9. Neu­rotech start-up Paradromics rais­es $20M to address brain-relat­ed dis­or­ders via next-gen brain-com­put­er interfaces

Neu­ralink vs. Paradromics vs. non-inva­sive plat­forms — quite a stim­u­lat­ing space to track

 

Wish­ing you and yours a hap­py and healthy back-to-school and month of September,

The Sharp­Brains Team

Alzheimer’s & Dementia researchers challenge FDA’s approval of Aduhelm given lack of evidence for beta-amyloid as a marker

by

Doc­tors Blast Bio­gen Alzheimer Approval as ‘Reg­u­la­to­ry Fail­ure’ (Bloomberg):

Top researchers who advised the U.S. Food and Drug Admin­is­tra­tion on Bio­gen Inc.’s Alzheimer’s drug blast­ed the agency for approv­ing it, call­ing the deci­sion a “reg­u­la­to­ry fail­ure” that is “at odds with the evi­dence.” [Read more…] about Alzheimer’s & Demen­tia researchers chal­lenge FDA’s approval of Aduhelm giv­en lack of evi­dence for beta-amy­loid as a marker

Update: Moderate lifetime drinking may lead to lower Alzheimer-related beta amyloid deposits in the brain

by

__

Time for a new edi­tion of Sharp­Brains’ e‑newsletter.

#1. First of all, it’s not all bad news this month. Study finds that mod­er­ate life­time drink­ing may lead to low­er Alzheimer-relat­ed beta amy­loid deposits in the brain

#2. And, talk about per­son­al­ized med­i­cine! This fas­ci­nat­ing study show­ing how brain imag­ing (fMRI) + machine learn­ing + inten­sive, non-inva­sive neu­rostim­u­la­tion = tar­get­ed treat­ments that can max­i­mize effi­ca­cy and min­i­mize side effects: Rein­vent­ing depres­sion treat­ment via tran­scra­nial mag­net­ic brain stim­u­la­tion (TMS)

#3. Also, not a minute too soon … Med­i­ta­tion apps have gone main­stream in the covid-19 era and Dig­i­tal health start-ups raised a record $3.1 bil­lion in Q1; focus will like­ly evolve from providers to con­sumers and employers

#4. Fyi, a very time­ly vir­tu­al event com­ing Tues­day April 28th, online: Explore strate­gies and tools to boost men­tal well­be­ing dur­ing (and after) Covid-19

#5. Now, “While Pear has an advan­tage over the com­pe­ti­tion in that its prod­ucts are backed by ran­dom­ized clin­i­cal tri­als, physi­cians and health plans are still work­ing out how to pre­scribe and pay for dig­i­tal ther­a­peu­tics.” The FDA clears Som­ryst, Pear’s dig­i­tal ther­a­peu­tic to treat chron­ic insomnia

#6. Net net, now is the time for indi­vid­ual and col­lec­tive action to shift to a health­i­er “new nor­mal” for all: 3 ways to pro­tect your men­tal health dur­ing –and after– COVID-19 (in Span­ish: Tres hábitos de higiene men­tal para vencer al COVID-19 y crear un futuro más salud­able). Want more? Enjoy these Three tips for wise minds to calm coro­n­avirus anxiety

#7. A small but impor­tant study for that hope­ful near future when uni­ver­si­ties and col­leges reopen their doors: Study finds mixed results of Adder­all as cog­ni­tive enhancer (seems to boost emo­tion more than cognition)

#8. But, first things first. “The Bee Gees song “Stayin’ Alive” reached #1 on the pop charts in 1977. Maybe it was the beat, maybe it was John Travolta’s danc­ing. Or maybe it’s that the Gibb broth­ers’ cen­tral lyric is quite lit­er­al­ly always play­ing in our head. Keep­ing us safe —that is, “stayin’ alive ”— is the pri­ma­ry mis­sion of the brain”

Enough with coro­n­avirus out­break. Any­thing else going on? Yes!

#9. The Right to Per­son­al Iden­ti­ty. The Right to Free Will. The Right to Men­tal Pri­va­cy. The Right to Equal Access to Men­tal Aug­men­ta­tion. The Right to Pro­tec­tion from Algo­rith­mic Bias. Will these five Neu­roR­ights help har­ness emerg­ing neu­rotech­nolo­gies for the com­mon good?

#10. “Today, the sci­en­tif­ic inves­ti­ga­tion of tran­scen­dent expe­ri­ences is, in my view, one of the most excit­ing fron­tiers in the sci­ence of well-being.” Tran­scend­ing Maslow’s famous “hier­ar­chy of needs” through Maslow’s own research on Peak Experiences

#11. You CAN have your cake and eat it too: Here’s a brain teas­er to stim­u­late your men­tal imagery, spa­tial rota­tion … and appetite

#12. Ques­tion: My first thought after con­grat­u­lat­ing myself on being so clever about some­thing? Tease your brain with these eight fun rid­dles…

 

Wish­ing you and yours a great month of May,

 

The Sharp­Brains Team

Study challenges the “seductive” amyloid hypothesis of Alzheimer’s disease (AD)

by

_____

Vas­cu­lar Health at Age 36 Tied to Brain Health at 70 (Med­page Today):

“A lon­gi­tu­di­nal study shed light on just how ear­ly peo­ple may want to start doing some­thing to reduce their demen­tia risk decades in the future.

Each 1% increase in Fram­ing­ham vas­cu­lar risk score at age 36 was asso­ci­at­ed with 9% high­er white mat­ter hyper­in­ten­si­ty vol­ume … (how­ev­er) Vas­cu­lar risk scores were not linked to beta-amy­loid sta­tus at any point. [Read more…] about Study chal­lenges the “seduc­tive” amy­loid hypoth­e­sis of Alzheimer’s dis­ease (AD)

New studies reinforce Education and Cognitive Reserve –instead of drugs targeting beta amyloid– as most promising avenue to prolong cognitive health and reduce dementia risk

by

dementia-progressionDemen­tia Risk Declines, And Edu­ca­tion May Be One Rea­son Why (NPR):

“Some encour­ag­ing news in the bat­tle against Alzheimer’s dis­ease and oth­er forms of demen­tia: The rate at which old­er Amer­i­cans are get­ting these con­di­tions is declin­ing. That’s accord­ing to [Read more…] about New stud­ies rein­force Edu­ca­tion and Cog­ni­tive Reserve –instead of drugs tar­get­ing beta amy­loid– as most promis­ing avenue to pro­long cog­ni­tive health and reduce demen­tia risk

Update: New brain science leads to new tools and to new thinking

by

We often view mem­o­ry, think­ing, emo­tions, as com­plete­ly sep­a­rate enti­ties, but they tru­ly are part of the same process. So, if we want to improve brain health, we need to pay atten­tion to the “weak link” in that process. In today’s soci­ety, man­ag­ing stress and neg­a­tive emo­tions is often that weak link, as we dis­cuss dur­ing Octo­ber Q&A ses­sion with par­tic­i­pants in Sharp­Brains’ new e‑course. Time now for Sharp­Brains’ Octo­ber 2012 eNewslet­ter, fea­tur­ing new sci­ence, new resources and new thinking.

New sci­ence:

New tools:

New think­ing:

That’s it for now. Have a Hap­py Halloween!

Pic cour­tesy of Big­Stock­Pho­to